Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed) | RFA HD 25 003

Opportunity Information: Apply for RFA HD 25 003

The Pediatric HIV/AIDS Cohort Study (PHACS) funding opportunity (RFA HD 25 003) is a National Institutes of Health (NIH) cooperative agreement (U19) meant to sustain and advance PHACS as a long-running, multi-site program focused on how HIV and HIV-related exposures affect health and development over time. The core aim is to support a program that is described as both transformative and agile, meaning it is expected to keep pace with changes in HIV treatment, prevention, and clinical care, while continuing to generate high-value longitudinal evidence. The scientific emphasis is on the developmental and clinical course of people living with HIV, including individuals with vertically acquired HIV (infection acquired during pregnancy, delivery, or breastfeeding), with particular attention to youth through reproductive age. Clinical trials are not allowed under this opportunity.

This opportunity sits in the discretionary funding category and uses a cooperative agreement mechanism, which typically indicates substantial NIH program involvement compared to a standard research project grant. The activity category spans education, health, income security, and social services, reflecting the broad real-world implications of pediatric and adolescent HIV outcomes, including medical, developmental, and psychosocial dimensions. The opportunity is associated with multiple CFDA numbers: 93.121, 93.242, 93.279, 93.855, and 93.865.

Eligibility is broad across U.S.-based organizations and public entities. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofits both with and without 501(c)(3) status (as long as they are not institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; small businesses; and other eligible entities. The announcement also explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and Indian/Native American tribal governments other than federally recognized.

At the same time, foreign involvement is clearly restricted. Non-domestic (non-U.S.) entities are not eligible to apply, non-domestic components of U.S. organizations are not eligible to apply, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. In practice, that means the applicant organization must be U.S.-based and the work supported by the award must be carried out without foreign components as NIH defines them.

The key administrative details provided include an original application due date of 2024-12-11, a stated award ceiling of $5,500,000, and an opportunity creation date of 2024-08-16. The number of expected awards is not specified in the provided source. Overall, this NOFO is designed to keep PHACS operating as a major U.S. research infrastructure for understanding long-term outcomes of pediatric and adolescent HIV, especially as affected individuals move through adolescence into adulthood and reproductive years, while staying within a non-clinical-trial research framework.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.242, 93.279, 93.855, 93.865.
• This funding opportunity was created on 2024-08-16.
• Applicants must submit their applications by 2024-12-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $5,500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HD 25 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: